Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press326BONE SARCOMASСАРКОМЫ КОСТЕЙNew therapeutic approaches in the treatment of chondrosarcomaНовые терапевтические подходы в лечении хондросаркомAkhovA. O.АховА. О.
Russian Federation

Moscow

г. Москва

Andy.akhov@gmail.comTeplyakovV. V.ТепляковВ. В.
Russian Federation

Moscow

г. Москва

FedenkoA. A.ФеденкоА. А.
Russian Federation

Moscow

г. Москва

SergeevP. S.СергеевП. С.
Russian Federation

Moscow

г. Москва

LiY. A.ЛиЯ. А.
Russian Federation

Moscow

г. Москва

ShaposhnikovA. A.ШапошниковА. А.
Russian Federation

Moscow

г. Москва

LazukinA. V.ЛазукинА. В.
Russian Federation

Moscow

г. Москва

Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian FedertionФГБУ «Российский научный центр рентгенорадиологии» Минздрава РоссииN.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian FederationФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России160420179216211501202215012022Copyright ©; 2017, Akhov A.O., Teplyakov V.V., Fedenko A.A., Sergeev P.S., Li Y.A., Shaposhnikov A.A., Lazukin A.V.Copyright ©; 2017, Ахов А.О., Тепляков В.В., Феденко А.А., Сергеев П.С., Ли Я.А., Шапошников А.А., Лазукин А.В.2017Akhov A.O., Teplyakov V.V., Fedenko A.A., Sergeev P.S., Li Y.A., Shaposhnikov A.A., Lazukin A.V.Ахов А.О., Тепляков В.В., Феденко А.А., Сергеев П.С., Ли Я.А., Шапошников А.А., Лазукин А.В.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/326

Chondrosarcoma is the second most common malignant neoplasm of the skeleton, the complexity of its treatment is due to its radiation and chemoresistance, which significantly reduces the therapeutic potential of the treating doctor. In this article will be considered one of the ways to influence this tumor – the Hedgehog signaling pathway.

Хондросаркома – второе по распространенности злокачественное новообразование скелета, сложность в лечении которой определяется ее рефрактерностью к химио- и лучевой терапии, что существенно сокращает терапевтические возможности лечащего врача. В этой статье будет рассмотрен один из потенциальных способов воздействия на данную опухоль – сигнальный путь Hedgehog.

chondrosarcomaHedgehog pathwaytargeted therapyхондросаркомасигнальный путь Hedgehogтаргетная терапия1. Nusslein-Volhard et al. Nature. 1980, v. 287, p. 795-801.Nusslein-Volhard et al. Nature. 1980, v. 287, p. 795-801.2. Taipale et al. Nature. 2002, v. 418, p. 892.Taipale et al. Nature. 2002, v. 418, p. 892.3. Stone et al. Nature. 1996, v. 384, p. 129.Stone et al. Nature. 1996, v. 384, p. 129.4. Bovée J.V.M.G., Cleton-Jansen A.M., Taminiau A.H.M., Hogendoorn P.C.W. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005, v. 6 (8), p. 599-607.Bovée J.V.M.G., Cleton-Jansen A.M., Taminiau A.H.M., Hogendoorn P.C.W. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005, v. 6 (8), p. 599-607.5. VanOosterwijk J.G., HerpersB.,Meijer D. et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro:BCL-2 family members cause chemoresistance. Ann. Oncol. 2012, v. 23 (6), p. 1617-1626.VanOosterwijk J.G., HerpersB.,Meijer D. et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro:BCL-2 family members cause chemoresistance. Ann. Oncol. 2012, v. 23 (6), p. 1617-1626.6. Wyman J.J., Hornstein A.M., Meitner P.A. et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J. Orthop. Res. 1999, v. 17 (6), p. 935-940.Wyman J.J., Hornstein A.M., Meitner P.A. et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J. Orthop. Res. 1999, v. 17 (6), p. 935-940.7. Frezza A.M., Cesari M., Baumhoer D. et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur. J. Cancer. 2015, v. 51 (3), p. 374-381.Frezza A.M., Cesari M., Baumhoer D. et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur. J. Cancer. 2015, v. 51 (3), p. 374-381.8. Murphey M.D., Walker E.A., Wilson A.J., Kransdorf M.J., Temple H.T., Gannon F.H. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologicpathologic correlation. Radiographics. 2003, v. 23 (5), p. 1245-1278.Murphey M.D., Walker E.A., Wilson A.J., Kransdorf M.J., Temple H.T., Gannon F.H. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologicpathologic correlation. Radiographics. 2003, v. 23 (5), p. 1245-1278.9. Van Oosterwijk J.G., Anninga J.K., Gelderblom H., Cleton-Jansen A.M., Bovee J.V. Update on targets and novel treatment optionsfor high-grade osteosarcoma and chondrosarcoma. Hematol. Oncol. Clin. North Am. 2013, v. 27 (5), p. 1021-1048.Van Oosterwijk J.G., Anninga J.K., Gelderblom H., Cleton-Jansen A.M., Bovee J.V. Update on targets and novel treatment optionsfor high-grade osteosarcoma and chondrosarcoma. Hematol. Oncol. Clin. North Am. 2013, v. 27 (5), p. 1021-1048.10. Zhang Y., Kalderon D. Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature. 2001, v. 410 (6828), p. 599-604.Zhang Y., Kalderon D. Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature. 2001, v. 410 (6828), p. 599-604.11. Daya-GrosjeanL.,Couve-PrivatS.SonicHedgehog signaling in basal cell carcinomas. CancerLett. 2005, v. 225 (2), p. 181-192.Daya-GrosjeanL.,Couve-PrivatS.SonicHedgehog signaling in basal cell carcinomas. CancerLett. 2005, v. 225 (2), p. 181-192.12. Rubin L.L., De Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006, v. 5 (12), p. 1026-1033.Rubin L.L., De Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006, v. 5 (12), p. 1026-1033.13. Tiet T.D., Hopyan S., Nadesan P. et al. Constitutive Hedgehog signaling in chondrosarcoma up-regulatestumor cell proliferation. Am. J. Pathol. 2006, v. 168 (1), p. 321-330.Tiet T.D., Hopyan S., Nadesan P. et al. Constitutive Hedgehog signaling in chondrosarcoma up-regulatestumor cell proliferation. Am. J. Pathol. 2006, v. 168 (1), p. 321-330.14. Campbell V.T., Nadesan P., Ali S.A. et al. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol. Cancer Ther. 2014, v. 13 (5), p. 1259-1269.Campbell V.T., Nadesan P., Ali S.A. et al. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol. Cancer Ther. 2014, v. 13 (5), p. 1259-1269.15. Xiang W., JiangT., Guo F. et al. Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis. Oncol. Rep. 2014, v. 32 (4), p. 1622-1630.Xiang W., JiangT., Guo F. et al. Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis. Oncol. Rep. 2014, v. 32 (4), p. 1622-1630.16. Sun Y., Guo W., Ren T. et al. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 2014, v. 5, e979.Sun Y., Guo W., Ren T. et al. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 2014, v. 5, e979.